BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Idilman R, Arat M. Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation. Expert Rev Anti Infect Ther 2011;9:641-52. [PMID: 21819330 DOI: 10.1586/eri.11.79] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Suo P, Cheng YF, Huang XJ. [Vaccination of hematopoietic stem cell transplantation patients]. Zhonghua Xue Ye Xue Za Zhi 2019;40:344-7. [PMID: 31104452 DOI: 10.3760/cma.j.issn.0253-2727.2019.04.018] [Reference Citation Analysis]
2 Türker K, Albayrak M, Öksüzoğlu B, Balc E, Oğan MC, Iskender G, Altuntaş F. Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma: a report of two cases and review of the literature. Eur J Gastroenterol Hepatol 2015;27:39-45. [PMID: 25076063 DOI: 10.1097/MEG.0000000000000115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Ataca Atilla P, Yalçıner M, Atilla E, İdilman R, Beksaç M. Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib. Turk J Haematol 2019;36:266-73. [PMID: 31368290 DOI: 10.4274/tjh.galenos.2019.2019.0103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Lee DG. Vaccination of hematopoietic stem cell transplantation recipients: perspective in Korea. Infect Chemother 2013;45:272-82. [PMID: 24396628 DOI: 10.3947/ic.2013.45.3.272] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
5 Ariza-Heredia EJ, Chemaly RF. Practical review of immunizations in adult patients with cancer. Hum Vaccin Immunother 2015;11:2606-14. [PMID: 26110220 DOI: 10.1080/21645515.2015.1062189] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
6 Turker K, Oksuzoglu B, Balci E, Uyeturk U, Hascuhadar M. Awareness of hepatitis B virus reactivation among physicians authorized to prescribe chemotherapy. Eur J Intern Med 2013;24:e90-2. [PMID: 23953849 DOI: 10.1016/j.ejim.2013.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
7 Han L, Zhou J, Zhou K, Zhu X, Zhao L, Fang B, Yin Q, Wei X, Zhou H, Li L, Xu B, Zhang J, Song Y, Gao Q. Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus. J Immunother Cancer 2020;8:e000927. [PMID: 32792360 DOI: 10.1136/jitc-2020-000927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Jaillais A, Herber-Mayne A, D'Alteroche L, Landau A, Merrouche Y, Vignot S. [HBV infection: Screening and treatment for oncology patients]. Bull Cancer 2018;105:162-70. [PMID: 29066086 DOI: 10.1016/j.bulcan.2017.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012;20:2999-3008. [PMID: 22933131 DOI: 10.1007/s00520-012-1576-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]